NR2C1 and sickle cell disease: Such interventions would exploit the mechanistic parallels between HPFH mutations and TR2/TR4 inactivation, leveraging endogenous γ-globin activation to ameliorate sickle cell disease or β-thalassemia while avoiding pleiotropic effects.